Case Report

“Hepatic Superscan” on a PET-CT scan of a patient with metastatic breast carcinoma

Moriarty HK, Buckley BW, and Ridge CA*

1,2 Department of Radiology, University College Dublin, Mater Misericordiae University Hospital, Ireland

Correspondence to: Carole A Ridge, Department of Radiology, University College Dublin, Mater Misericordiae University Hospital, Ireland, Tel: +353874192582; E-mail: cridge@mater.ie

Received: March 01, 2017; Accepted: March 20, 2017; Published: March 23, 2017

Case study

A 50-year-old female pT2N1 grade 3 infiltrating ductal carcinoma developed breast cancer metastasis to brain and liver 12 years after initial surgical resection. Multiple hormonal and cytotoxic agents were sequentially administered including letrozole, paclitaxel, eribulin and fulvestrant. Surveillance contrast enhanced Computed Tomography (CT) of the thorax abdomen and pelvis demonstrated low volume hepatic disease (Figure 1 A & B). Three months later, a surveillance positron emission tomography computed tomography (PET-CT) scan was performed to assess response to eribulin. Images were acquired post administration of oral and IV contrast (portovenous phase), performed 1 hour post injection of 393 (megabecquerel) MBq of fluorodeoxyglucose (F18-FDG). The radiation dose attributed to PET scan acquisition was 12.5 millisievert (mSv), with an additional approximate dose length product (DLP) from the CT component was 626 milligray (mGy), giving a total radiation of approximately 19.5 mSv. This demonstrated diffuse hepatic tracer uptake, and interval growth of bilobar liver metastases, with concomitant paucity of gastric, bowel, cardiac and renal tracer uptake, a rare appearance described as “hepatic superscan” (Figures B 1-3). In light of the increase in number and size of liver lesions, the appearance likely represents diffuse hepatic progression of disease from which the patient died two months later.

Discussion

PET-CT is a useful tool in the staging of recurrent or metastatic breast cancer and in evaluating the response of locally advanced and metastatic breast cancer to treatment [1]. The liver is the most common site of haematogenous metastasis. Liver metastases are 18 - 40 times more common than a primary liver malignancy [2]. PET CT is considered useful in systemic therapy assessment and surveillance for liver metastases [3].

“Hepatic superscan” is an uncommon PET-CT finding. The term is applied when intense hepatic FDG uptake is seen in combination with low cardiac, bowel, renal and brain FDG uptake, similar to skeletal scintigraphy [4]. This finding may be seen in extensive hepatic involvement by malignancy such as metastatic disease, lymphoma or hepatocellular carcinoma [5-7]. Hepatic superscan appearance has also rarely been reported in non-malignant conditions including tuberculosis [8].
Moriarty HK (2017) “Hepatic Superscan” on a PET-CT scan of a patient with metastatic breast carcinoma

References


Figure 2 C. Sagittal reconstructed fused PET-CT image using bone windows demonstrates low grade FDG uptake in skeletal metastases, less than the adjacent diffuse hepatic uptake.

Copyright: ©2017 Moriarty HK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.